



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	168572	Silica Liquid
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	FIT-BioCeuticals Limited	
<b>Postal Address</b>	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
<b>ARTG Start Date</b>	2/02/2010	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Silica Liquid

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	28/05/2020
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Maintain/support collagen formation  
Maintain/support collagen health  
Maintain/support hair health  
Maintain/support nail health/strength/thickness  
Maintain/support connective tissue health  
Maintain/support bone health  
Maintain/support bone mass/density/integrity in pre-menopausal women  
Maintain/support bone strength in pre-menopausal women  
Help maintain/support bone mineralisation in pre-menopausal women  
Helps maintain/support joint cartilage health  
Maintain/support tendon health  
Maintain/support skin health  
Maintain/support skin integrity/structure

### Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.  
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Contains benzoates' (or words to this effect) if the medicine contains two or more benzoate sources or 'Contains [insert the approved name of benzoate used]' (or words to this effect) if product contains one benzoate source.

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Liquid, multipurpose

**Route of Administration** Topical  
Oral

**Visual Identification**

**Active Ingredients**

colloidal anhydrous silica	30 mg/mL
Equivalent: silicon	14 mg/mL

**Other Ingredients (Excipients)**

citric acid

Flavour

hypromellose

purified water

sodium benzoate

Stevia rebaudiana

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary